GlassScriptPhysician profile
Kathleen Engeln
NPI 1720441496
$7,051.56
in general payments reported to CMS, 2019-2025
21 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $263 · 2021: $329 · 2022: $377 · 2023: $2,301 · 2024: $2,450 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,012 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,011.71 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,630.33 | 2020-2025 | |
| Amgen INC. | $782.60 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $664.93 | 2020-2025 | |
| Galderma Laboratories, L.P. | $664.14 | 2021-2025 | Nemluvio, Dysport, Aklief |
| Regeneron Healthcare Solutions, INC. | $513.02 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $457.20 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $449.08 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $404.22 | 2020-2025 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $274.25 | 2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $204.53 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $193.95 | 2022-2024 | Winlevi |
| Incyte Corporation | $152.14 | 2023-2025 | Opzelura |
| Pfizer INC. | $148.92 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.11 | 2023-2024 | Spevigo |
| Ucb, INC. | $118.81 | 2023-2025 | Bimzelx, Cimzia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Journey Medical Corporation | $44.99 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $42.48 | 2024 | Tremfya |
| Organon LLC | $41.54 | 2024-2025 | Hadlima |
| Verrica Pharmaceuticals INC. | $28.86 | 2024 | Ycanth |
| Mimedx Group, INC. | $26.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Engeln listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.